Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide ATG 120 mg plus metformin in progressive advanced well-differentiated gastrointestinal or lung carcinoids
2015-004626-34Phase 2Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide and metformin in apudoma (NET), Carcinoid Tumor (CT), Bronchopulmonary Carcinoid (BPC) and 1 more, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Safety. Started Dec 2020; status: active.
02
Drugs
lanreotidemetformin
03
Conditions
apudoma (NET)Carcinoid Tumor (CT)Bronchopulmonary Carcinoid (BPC)gastrointestinal carcinoid tumor
Beyond the preview
Go deeper on 2015-004626-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004626-34.